PEPTIDE THERAPY: WHAT ACTUALLY WORKS, WHAT DOESN’T, AND WHAT PATIENTS SHOULD KNOW
Peptides are everywhere right now.
In February 2026, HHS Secretary Robert F. Kennedy Jr. announced that 14 peptides previously restricted by the FDA would be restored to legal compounding status. Overnight, the conversation moved from wellness TikTok into mainstream news. Patients started asking their doctors about BPC-157, CJC-1295, and Thymosin Alpha-1 — compounds most primary care physicians had never been asked about before.
This guide is not promotional. We’re an independent primary care practice in Midtown Manhattan on the leading edge of medicine, and our job is to help patients make sense of what’s actually going on.
Here’s what we know.
Short version: The GLP-1 medications — semaglutide, tirzepatide — are peptides. They are among the most rigorously studied drugs in modern medicine. Everything else being discussed right now sits somewhere on a spectrum from genuinely promising to completely unsubstantiated. This guide will help you figure out t risks and the benefits so you can make an informed decision.
What are peptides, in plain English?
At a basic level, peptides are short chains of amino acids.
If proteins are full-length sentences, peptides are more like text messages. Short, targeted, and designed to get a specific point across.
In your body, those messages might say: release a hormone, repair tissue, build collagen.
The key point: peptides don’t do things directly. They tell your body to do things. And what your body does with that signal depends on context.
Aren’t peptides already used in real medicine?
Yes. And this is where things get confusing.
Before peptides became a wellness trend, they were already central to modern medicine. Insulin is a peptide. It’s life-saving. GLP-1 medications like semaglutide are heavily studied, have clear dosing, and show consistent results in large human trials.
These are the established peptides. Everything else you’re seeing online is, in one way or another, trying to borrow that credibility.
What did RFK Jr. actually do and why does it matter?
In late 2023, the FDA moved 19 widely used peptides to a restricted list, effectively preventing compounding pharmacies from preparing them. Many clinicians argued the restrictions were overbroad — that the FDA had applied a blanket policy to compounds with very different evidence profiles.
On February 27, 2026, HHS reversed course. It is expected that 14 of those 19 peptides will be restored to legal compounding status this summer. This means licensed compounding pharmacies can prepare them again under a physician’s prescription.
What it does not mean: these peptides are FDA-approved. They remain off-label therapeutics. Reclassification means legal access with physician supervision — not a green light to order them online without a prescription.
What’s the difference between legal compounding and buying peptides online?
This is where most patients get confused.
Legal compounding means a licensed pharmacy, inspected by regulators, prepares a compound to a physician’s prescription with quality controls in place.
Online “research peptides” are sold under the fiction that they’re for laboratory use only. They are not manufactured for human use, have no quality controls, and a meaningful portion do not match their labels. One analysis published in JAMA found that nearly one quarter of products sold online contained undisclosed compounds. Patients are paying up to $500 a month for products that may contain unknown ingredients or contaminants.
The RFK reclassification does not make online research peptides any safer. It restores legal physician-supervised access. Those are different things.
What peptides are people actually taking right now?
Most fall into a few categories:
- Growth hormone-related peptides: sermorelin, ipamorelin, tesamorelin, CJC-1295
- Recovery peptides: BPC-157, TB-500 (Thymosin Beta-4)
- Skin and longevity peptides: GHK-Cu
- GLP-1/GIP class peptides: semaglutide, tirzepatide — and what comes next (more on this below)
- Combinations or “stacks”: For example the so-called Glow Stack or Wolverine stack
They’re marketed as simple upgrades. They’re not that simple.
What does a “Glow Stack” actually do in the body?
A common stack includes GHK-Cu, BPC-157, and TB-500.
Here’s what’s happening biologically:
GHK-Cu helps regulate collagen structure — think improving the scaffolding of your skin.
BPC-157 interacts with pathways that increase blood vessel formation (angiogenesis) — think building new roads to bring nutrients to tissue.
TB-500 affects how cells move and reorganize — think directing repair crews where to go.
Here’s the catch. Peptides act on shared biological systems. The same pathways that help healing, improve blood flow, and rebuild tissue are also involved in tumor growth and abnormal tissue proliferation. You are not turning on a healing switch. You are influencing a system that does multiple things depending on context. So the question is not whether these peptides do something — it’s whether what they do is net positive in your specific body, at this specific moment, given your specific health situation.
Do peptides actually work?
Some do. Many don’t.
GLP-1 medications: strong evidence, large human trials, consistent results.
Tesamorelin: meaningful data in a specific use case, FDA-approved.
Most others: limited human data, significant marketing.
This is an area where the story is often well ahead of the science.
What is tesamorelin and why is it different from most peptides being discussed?
Tesamorelin is a growth hormone-releasing hormone analogue — meaning it stimulates the pituitary gland to release growth hormone rather than introducing growth hormone directly.
It is FDA-approved for a specific indication: the reduction of excess abdominal fat in HIV-positive patients with lipodystrophy, a condition where antiretroviral therapy causes abnormal fat redistribution.
What makes tesamorelin notable is that it went through large randomized controlled trials in humans. It has a defined patient population with a measurable outcome. The approval is narrow and specific, not a broad wellness claim.
In fact, tesamorelin is often cited by peptide advocates as proof that the whole category is legitimate. It does not prove that. It proves that one specific peptide, used for one specific indication, in one specific patient population, has been studied properly. That standard has not been met for most of what is currently being marketed.
What about retatrutide — the “triple agonist” everyone is talking about?
This one deserves its own section because the social media conversation around it has outpaced what the actual clinical picture looks like right now.
Retatrutide (LY3437943) is a peptide developed by Eli Lilly that simultaneously targets three hormone receptors: GLP-1, GIP, and glucagon. The GLP-1 and GIP mechanisms are shared with tirzepatide (Mounjaro, Zepbound). The glucagon receptor activation is the addition — it increases energy expenditure and promotes fat oxidation in a way that dual agonists don’t directly target.
The Phase 3 data coming out of the TRIUMPH program is legitimately striking. TRIUMPH-4, which reported in December 2025, showed 28.7% average weight loss at 68 weeks at the 12mg dose. For context: semaglutide (Wegovy) showed 16.9% in its pivotal trial. Tirzepatide (Zepbound) showed 22.5% at 72 weeks. Retatrutide’s numbers, if they hold across the full TRIUMPH program, would represent the highest weight loss efficacy ever recorded in a pharmaceutical trial — approaching what bariatric surgery produces.
Current status: As of mid 2026, retatrutide has no FDA approval and is not available by commercial prescription. Eli Lilly is still completing Phase 3 trials across the TRIUMPH program. Six additional trial readouts are expected throughout the rest of the year. The NDA submission is projected for late 2026 or early 2027, which would put FDA review completion and potential approval at late 2027 at the earliest, with commercial availability more likely in 2028.
However: Compounding pharmacies and gray market research vendors are already selling it online. This is the same situation as every other unregulated peptide: unknown purity, no quality controls, no physician oversight, and you are ahead of the evidence. The TRIUMPH program is still running. We don’t fully know the long-term safety profile of triple agonism yet. One specific finding worth noting: TRIUMPH-4 reported dysesthesia (abnormal skin sensations) in 20.9% of participants — a side effect not seen at this rate with semaglutide or tirzepatide, and one that is still being characterized.
What about NAD+, collagen peptides, and the things I see on Instagram?
NAD+ is not a peptide. It’s a coenzyme. It’s often bundled with peptide protocols in wellness clinics, and it does play a real role in cellular energy metabolism. The IV NAD+ market is large and mostly outpacing its evidence base. Oral NAD+ precursors (NMN, NR) have more accessible delivery but the absorption and clinical benefit data is still very limited in healthy people.
Collagen peptides (the powders you add to coffee) are hydrolyzed protein fragments. Your digestive system breaks them down into amino acids, which your body then uses for whatever it needs — not necessarily collagen synthesis in your skin. The evidence for oral collagen peptides improving skin elasticity is weak and the studies are mostly funded by manufacturers. The evidence for general protein intake supporting skin and connective tissue is stronger. If you’re eating enough protein, the marginal benefit of collagen peptides specifically is unclear.
The peptide serums and creams: most peptide molecules are too large to penetrate the skin barrier intact. GHK-Cu topicals at concentrations above 1% have some reasonable evidence for skin-specific effects. Everything else in the aisle is mostly wishful biochemistry.
What are the real risks of peptide therapy?
There are three main types.
1) Product risk: what are you actually getting?
Many peptides sold online come from unregulated compounding sources or gray market vendors. Risks include contamination with heavy metals and endotoxins, incorrect or unlisted ingredients, and inconsistent dosing. A meaningful portion of products sold online do not match their labels.
2) Efficacy risk: are you just wasting money?
Many protocols promise better recovery, more energy, improved skin. But if you ask what we’re measuring to prove this is working, there is often no clear answer and no baseline to compare against.
3) Biological risk: unintended effects
Peptides interact with blood vessel growth, hormone signaling, immune response, and cell growth pathways. These are not small adjustments — they are central biological systems. And for many peptides, we do not have long-term human data on what consistent use does over years.
Who should not be on peptide therapy?
History of cancer: Peptides that influence growth and vascular pathways require extreme caution in patients with a history of malignancy. This is a serious risk.
Relevant family history: GLP-1 medications are contraindicated in patients with a personal or family history of medullary thyroid cancer or MEN2 syndromes. If no one is asking you about this before prescribing, that’s a red flag.
Not current on cancer screening: Before starting any therapy that influences growth pathways, you should be current on colonoscopy, mammography, and other age-appropriate screening. You want to know there is nothing already present before influencing those systems.
Do I need a doctor for peptide therapy?
Yes.
These are not typical supplements. They require prescriptions, affect real biological systems, and require a genuine risk-benefit discussion specific to your health history. If that process isn’t happening, it’s not ethical medical care.
Why is everyone talking about peptides right now?
Because it’s a compelling idea, the regulatory environment just shifted in a visible way, and targeted molecules that optimize your body are easy to market. At the same time, regulation is still evolving and misinformation spreads faster than clinical evidence. High demand plus mixed-quality information is a combination that benefits marketers more than patients.
What should I do if I'm considering peptide therapy?
Start with a real conversation with a physician who knows your history. Understand what you’re trying to treat, what the evidence supports for that specific goal, and what the risks are given your specific health situation.
If it makes sense, proceed carefully with physician supervision and pharmaceutical-grade sourcing. If it doesn’t, don’t let aggressive marketing and wishful thinking pressure you into it.
